DYRK1B and melanoma: Finally, similar results were obtained in the A375 melanoma cell line (BRAFV600E) (Supplemental Fig. 1c), where selumetinib caused a dose-dependent inhibition of ERK1/2 signalling and an increase in expression of DYRK1B as well as BIMEL, which is known to be repressed by the ERK1/2 pathway [46].